Indivior avoids multi-state antitrust trial with $100m payout

Case involved the alleged monopolisation of an opioid addiction treatment | More than 40 attorneys general had filed complaints against the pharma company.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BioNTech fires shots at Moderna's next-generation vaccine

20 February 2026 The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.

Careers

Mintz gains ex-Winston & Strawn partner and ITC expert

20 February 2026 The new hire has “deep experience in high-stakes International Trade Commission proceedings”, whose specialisms include medical devices, pharma and genomics.

Americas

Abbott unit defends European protection for heart valve ‘cuff’ design

19 February 2026 An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.

More features

BioNTech fires shots at Moderna's next-generation vaccine

Mintz gains ex-Winston & Strawn partner and ITC expert

Abbott unit defends European protection for heart valve ‘cuff’ design

Natera targets ex-employee over mass file download before rival move

Hogan Lovells makes senior public and administrative hire in Italy

Danaher moves to acquire Masimo in $9.9bn deal

Generic rival blocked as AZ defends diabetes stronghold

Emotional Perception exclusive: ‘We are now very much open for business’

Indivior avoids multi-state antitrust trial with $100m payout

More on this story

Editor's picks

Editor's picks

More features